TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

ConclusionTP53 mutations are potential prognostic markers that can be used to further improve the accuracy of predicting survival and disease-free survival times of cancer patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

.
Source: Health Communication - Category: Health Management Authors: Source Type: research
.
Source: Health Communication - Category: Health Management Authors: Source Type: research
.
Source: Health Communication - Category: Health Management Authors: Source Type: research
Conclusions-AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs. PMID: 31835965 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
.
Source: Psychology, Health and Medicine - Category: International Medicine & Public Health Authors: Source Type: research
.
Source: Psychology, Health and Medicine - Category: International Medicine & Public Health Authors: Source Type: research
We examined common patterns of home environmental modification (HEM) use and associated major (including disability-, cardiovascular-, and cancer-related) health conditions and events among older women. METHODS: Women, age 78.6 ±6.3 yea...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
i am just devastated. i graduated from a great med school, finished residency at a reputable institution...Im not the greatest test taker but ive always done average at the least. i hate making excuses but i went into it less than prepared and i knew it. i've been a bit overwhelmed at my new job (do i tell them?) and i just got news earlier that week that my sibling's cancer is back which has been very rough on me. uuuggghhh...abem's website is terrible to navigate but from what i can... f me...74 on abem. now what?!
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Emergency Medicine Source Type: forums
Unrelenting pain in her hips and weeks of insomnia left Nelly Valbuena desperate for relief from her metastatic breast cancer
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Adenocarcinoma | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Databases & Libraries | Endometrial Cancer | Genetics | Head and Neck Cancer | Hepatocellular Carcinoma | Kidney Cancer | Leukemia | Liver Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Serous Carcinoma | Squamous Cell Carcinoma | Statistics | Study